Approximately one-third of patients with migraine reported using opioids to treat their symptoms, a practice that contrasts with current guidelines.
The USPSTF has updated its 2014 evidence report on the potential benefits and harms of interventions to prevent illicit drug use in children, adolescents, and young adults.
An opinion piece highlights the growing concerns among medical professionals about the exacerbating effects the COVID-19 pandemic may have among people with opioid use disorder.
Patients on hemodialysis who use opioids concurrently with a short-acting benzodiazepine are especially at risk for early death, a study found.
In the cohort without baseline MDD, baseline nonmedical opioid use was significantly associated with an increased risk of incident depressive symptoms, but not MDD, over 3 years.
Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.
Financial incentives improved X-waiver training completion and buprenorphine prescribing rates in emergency department physicians.
People who receive additional treatment following medically managed opioid withdrawal have reduced mortality compared with those who do not receive treatment.
Few primary care physicians report interest in treating patients with opioid use disorder.
Despite conflicting evidence, a third of primary physicians do not perceive OUD medication to be more effective than nonmedication treatment.